focus -WSS

focus

author：fashion 2025-09-27 09:53:57 - browse：6379

Amylyx founders — Justin Klee (left) and Joshua Cohen are the co-founders and co-CEOs of Amylyx Pharmaceuticals. Kayana Szymczak for STAT

Amylyx Pharmaceuticals said Friday that its treatment for ALS, called Relyvrio, failed to provide any benefit for patients in a large clinical trial — a stunning outcome that now has the company considering a voluntary withdrawal of the approved medicine from the market.

“This is really hard for us, and it’s really hard for our team who care so much, but it’s so much harder for people with ALS and their families, and we have to keep that perspective,” said a somber Justin Klee, Amylyx’s co-founder and co-CEO, in an interview with STAT on Thursday evening.

In the Phase 3 study involving 664 people with ALS, Relyvrio failed to outperform a placebo on an ALS functional rating scale that measures the ability to perform daily living tasks, walk, breathe, speak, and swallow. The company did not provide detailed results for the study’s primary goal, but said the calculation for statistical significance was 0.67 — well above the 0.05 threshold for success and an indication that Relyvrio provided no benefit at all.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Wildfire smoke exposes gaps in outdoor worker protections
Next article： Big Tobacco's 'harm reduction': Is it for real, or a sham?

focus

WSS

With measles on the rise, a personal story of a devastating disease

HIV vaccine remains elusive. Immunologists keep trying new ideas

Philips to halt sales of sleep apnea machines in U.S.

Syphilis numbers in the United States reach record heights

Can we make enough H5N1 bird flu vaccine if there's a pandemic?

Helping hospitals and community health centers plan for resilience

hotspot

focus

leisure time

BioMarin wins approval for gene therapy to treat hemophilia A

10 reasons why health care startups fail

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

Merck, Johnson & Johnson CEOs will testify on high drug prices

Medical records are filled with copy

HIV vaccine remains elusive. Immunologists keep trying new ideas

Hepatitis C has a cure — but many Americans still lack access to it

Syphilis numbers in the United States reach record heights

Walensky prepares to leave CDC — and Congress — behind

Wegovy leads to weight loss. Can it treat depression, too?

hotspot

Biogen walks away from Aduhelm, years after polarizing approval

NVIDIA and Google execs on the future of AI and drug discovery

Analysis of pharma R&D ranks Novo Nordisk, J&J above their peers

Big Tobacco's 'harm reduction': Is it for real, or a sham?

10 reasons why health care startups fail

Investment in vaccine development is lagging, report finds

focus

hotspot

focus

knowledge